EFM
E Fund Management’s Celldex Therapeutics CLDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-10,125
| Closed | -$184K | – | 409 |
|
|
2025
Q1 | $184K | Sell |
10,125
-660
| -6% | -$12K | 0.01% | 367 |
|
|
2024
Q4 | $273K | Buy |
+10,785
| New | +$273K | 0.01% | 331 |
|
|
2024
Q3 | – | Sell |
-7,258
| Closed | -$269K | – | 358 |
|
|
2024
Q2 | $269K | Sell |
7,258
-1,788
| -20% | -$66.2K | 0.01% | 248 |
|
|
2024
Q1 | $380K | Buy |
9,046
+1,097
| +14% | +$46K | 0.02% | 234 |
|
|
2023
Q4 | $315K | Sell |
7,949
-516
| -6% | -$20.5K | 0.02% | 225 |
|
|
2023
Q3 | $233K | Sell |
8,465
-2,587
| -23% | -$71.2K | 0.02% | 232 |
|
|
2023
Q2 | $375K | Buy |
11,052
+2,781
| +34% | +$94.4K | 0.03% | 185 |
|
|
2023
Q1 | $298K | Buy |
8,271
+760
| +10% | +$27.4K | 0.02% | 225 |
|
|
2022
Q4 | $335K | Sell |
7,511
-6,767
| -47% | -$302K | 0.03% | 212 |
|
|
2022
Q3 | $401K | Buy |
14,278
+78
| +0.5% | +$2.19K | 0.04% | 183 |
|
|
2022
Q2 | $383K | Buy |
14,200
+6,362
| +81% | +$172K | 0.03% | 197 |
|
|
2022
Q1 | $267K | Buy |
+7,838
| New | +$267K | 0.01% | 240 |
|